|
|
|
|
LEADER |
00000cam a2200000 i 4500 |
001 |
SCIDIR_ocn893677301 |
003 |
OCoLC |
005 |
20231120111827.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
141016t20152015enka ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e rda
|e pn
|c E7B
|d OCLCO
|d N$T
|d OPELS
|d UIU
|d OCLCF
|d COO
|d EBLCP
|d YDXCP
|d OCLCQ
|d ABH
|d YDX
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCA
|d U3W
|d OCLCO
|d D6H
|d OCLCA
|d AU@
|d OCLCO
|d S2H
|d OCLCQ
|d OCLCO
|d OCLCA
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 892799587
|a 957736321
|a 958082063
|a 959328202
|a 959590633
|a 961932971
|a 1072028197
|a 1116017975
|
020 |
|
|
|a 9780128004999
|q (electronic bk.)
|
020 |
|
|
|a 0128004991
|q (electronic bk.)
|
020 |
|
|
|a 0128001860
|
020 |
|
|
|a 9780128001868
|
020 |
|
|
|a 1322639523
|q (ebk.)
|
020 |
|
|
|a 9781322639529
|q (ebk.)
|
020 |
|
|
|z 9780128001868
|
035 |
|
|
|a (OCoLC)893677301
|z (OCoLC)892799587
|z (OCoLC)957736321
|z (OCoLC)958082063
|z (OCoLC)959328202
|z (OCoLC)959590633
|z (OCoLC)961932971
|z (OCoLC)1072028197
|z (OCoLC)1116017975
|
050 |
|
4 |
|a QP356.2
|b .S464 2015eb
|
072 |
|
7 |
|a SCI
|x 070000
|2 bisacsh
|
082 |
0 |
4 |
|a 591.188
|2 23
|
100 |
1 |
|
|a Seneci, Pierfausto,
|e author.
|
245 |
1 |
0 |
|a Molecular targets in protein misfolding and neurodegenerative disease /
|c Pierfausto Seneci.
|
264 |
|
1 |
|a London :
|b Academic Press,
|c 2015.
|
264 |
|
4 |
|c �2015
|
300 |
|
|
|a 1 online resource (314 pages) :
|b illustrations (some color)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references at the end of each chapters and index.
|
588 |
0 |
|
|a Print version record.
|
520 |
|
|
|a Aimed at "drug discoverers"--I.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc
|
505 |
0 |
|
|a Cover; Title Page; Copyright Page; Dedication; Contents; Abbreviations; Chapter 1 -- Protein Misfolding, Neurodegeneration and Tau; 1.1 -- The neurodegeneration scenario; 1.2 -- Protein folding: physiological benefits and pathological consequences; 1.3 -- Tau: An intrinsically disordered, flexible, and aggregation-prone protein; 1.4 -- Tauopathies: Aggregation-prone tau in neurodegenerative disease (NDD); 1.4.1 -- Class 0 Tauopathies; 1.4.2 -- Class I Tauopathies; 1.4.3 -- Class II Tauopathies; 1.4.4 -- Class III Tauopathies; 1.4.5 -- Class IV Tauopathies; 1.4.6 -- Tau Mutations; References.
|
505 |
8 |
|
|a Chapter 2 -- Targeting the Protein Quality Control (PQC) Machinery2.1 -- Molecular chaperones, PQC, and neurodegeneration; 2.2 -- Molecular targets; 2.2.1 -- Hsp27; 2.2.2 -- Hsp70; 2.2.3 -- Hsp90; 2.3 -- Disease-modifying compounds; References; Chapter 3 -- Proteasomal Degradation of Soluble, Misfolded Proteins; 3.1 -- UPS-mediated degradation of misfolded proteins; 3.2 -- UPS-mediated degradation of misfolded proteins in NDDs; 3.3 -- UPS-targets; 3.3.1 -- CHIP; 3.3.2 -- USP14; 3.4 -- Disease-modifying compounds; References; Chapter 4 -- Unselective Disposal of Cellular Aggregates.
|
505 |
8 |
|
|a 4.1 -- Autophagy-mediated degradation of protein aggregates4.2 -- Autophagy-mediated degradation of protein aggregates in NDDs; 4.3 -- Macroautophagy-targets; 4.3.1 -- mTORC1; 4.4 -- Disease-modifying compounds; References; Chapter 5 -- Selective Disposal of Insoluble Protein Aggregates; 5.1 -- Aggrephagy-mediated degradation of protein aggregates; 5.2 -- Selective autophagy-mediated degradation of protein aggregates in NDDs; 5.3 -- Selective autophagy-targets; 5.3.1 -- p62; 5.3.2 -- HDAC6; 5.4 -- Disease-modifying compounds; References; Chapter 6 -- Assembly and Disassembly of Protein Aggregates.
|
505 |
8 |
|
|a 6.1 -- Introduction6.2 -- Disordered protein aggregates and ordered amyloid fibrils; 6.2.1 -- The Target: Interfering with (Neuro)toxic Tau Species in the Aggregation Process; 6.3 -- Chaperone-driven disaggregation of protein aggregates; 6.3.1 -- The Target: Hsp110; 6.4 -- Disease-modifying compounds; References; Conclusions; Index.
|
650 |
|
0 |
|a Molecular neurobiology.
|
650 |
|
0 |
|a Nervous system
|x Diseases.
|
650 |
1 |
2 |
|a Tauopathies
|x drug therapy
|0 (DNLM)D024801Q000188
|
650 |
1 |
2 |
|a Tauopathies
|x etiology
|0 (DNLM)D024801Q000209
|
650 |
|
2 |
|a Nervous System Diseases
|0 (DNLM)D009422
|
650 |
2 |
2 |
|a Molecular Targeted Therapy
|x methods
|0 (DNLM)D058990Q000379
|
650 |
2 |
2 |
|a Protein Folding
|x drug effects
|0 (DNLM)D017510Q000187
|
650 |
|
6 |
|a Neurobiologie mol�eculaire.
|0 (CaQQLa)201-0167529
|
650 |
|
6 |
|a Syst�eme nerveux
|x Maladies.
|0 (CaQQLa)201-0007359
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Zoology
|x General.
|2 bisacsh
|
650 |
|
7 |
|a Molecular neurobiology
|2 fast
|0 (OCoLC)fst01024815
|
650 |
|
7 |
|a Nervous system
|x Diseases
|2 fast
|0 (OCoLC)fst01036098
|
776 |
0 |
8 |
|i Print version:
|a Seneci, Pierfausto.
|t Molecular targets in protein misfolding and neurodegenerative disease.
|d London : Academic Press, �2015
|h xvii, 295 pages
|z 9780128001868
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780128001868
|z Texto completo
|